A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

PHASE3CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

June 6, 2018

Primary Completion Date

November 9, 2020

Study Completion Date

March 28, 2023

Conditions
Colitis, Ulcerative
Interventions
DRUG

AJM300

AJM300 film-coated tablets.

DRUG

Placebo

Placebo matched to AJM300 tablets.

Trial Locations (82)

Unknown

AJM300/CT3 trial site 41, Nagoya

AJM300/CT3 trial site 57, Nagoya

AJM300/CT3 trial site 63, Nagoya

AJM300/CT3 trial site 9, Toyoake

AJM300/CT3 trial site 33, Toyohashi

AJM300/CT3 trial site 42, Toyota

AJM300/CT3 trial site 39, Hirosaki

AJM300/CT3 trial site 49, Hirosaki

AJM300/CT3 trial site 11, Kashiwa

AJM300/CT3 trial site 51, Kashiwa

AJM300/CT3 trial site 73, Sakura

AJM300/CT3 trial site 54, Urayasu

AJM300/CT3 trial site 81, Matsuyama

AJM300/CT3 trial site 53, Kurume

AJM300/CT3 trial site 24, Tikushino

AJM300/CT3 trial site 55, Isesaki

AJM300/CT3 trial site 35, Fukuyama

AJM300/CT3 trial site 18, Asahikawa

AJM300/CT3 trial site 26, Asahikawa

AJM300/CT3 trial site 2, Sapporo

AJM300/CT3 trial site 3, Sapporo

AJM300/CT3 trial site 4, Sapporo

AJM300/CT3 trial site 79, Akashi

AJM300/CT3 trial site 34, Kobe

AJM300/CT3 trial site 64, Nishinomiya

AJM300/CT3 trial site 82, Kasama

AJM300/CT3 trial site 75, Tsukuba

AJM300/CT3 trial site 19, Morioka

AJM300/CT3 trial site 16, Takamatsu

AJM300/CT3 trial site 12, Kamakura

AJM300/CT3 trial site 14, Sagamihara

AJM300/CT3 trial site 32, Sagamihara

AJM300/CT3 trial site 13, Yokohama

AJM300/CT3 trial site 6, Yokohama

AJM300/CT3 trial site 47, Tsu

AJM300/CT3 trial site 46, Yokkaichi

AJM300/CT3 trial site 45, Sendai

AJM300/CT3 trial site 50, Sendai

AJM300/CT3 trial site 78, Sendai

AJM300/CT3 trial site 22, Nagaoka

AJM300/CT3 trial site 15, Kurashiki

AJM300/CT3 trial site 70, Kurashiki

AJM300/CT3 trial site 77, Higashiosaka

AJM300/CT3 trial site 76, Sayama

AJM300/CT3 trial site 10, Takatsuki

AJM300/CT3 trial site 40, Ageo

AJM300/CT3 trial site 5, Ageo

AJM300/CT3 trial site 72, Tokorozawa

AJM300/CT3 trial site 17, Hamamatsu

AJM300/CT3 trial site 60, Ashikaga

AJM300/CT3 trial site 29, Shimotsuga

AJM300/CT3 trial site 71, Utsunomiya

AJM300/CT3 trial site 61, Bunkyo

AJM300/CT3 trial site 68, Bunkyo

AJM300/CT3 trial site 59, Chiyoda City

AJM300/CT3 trial site 30, Chūō

AJM300/CT3 trial site 31, Hachiōji

AJM300/CT3 trial site 56, Minato

AJM300/CT3 trial site 66, Minato

AJM300/CT3 trial site 80, Mitaka

AJM300/CT3 trial site 38, Shinagawa

AJM300/CT3 trial site 21, Shinjuku

AJM300/CT3 trial site 52, Shinjuku

AJM300/CT3 trial site 8, Shūnan

AJM300/CT3 trial site 23, Kofu

AJM300/CT3 trial site 44, Chiba

AJM300/CT3 trial site 43, Fukuoka

AJM300/CT3 trial site 58, Fukuoka

AJM300/CT3 trial site 69, Fukuoka

AJM300/CT3 trial site 67, Gifu

AJM300/CT3 trial site 28, Hiroshima

AJM300/CT3 trial site 36, Hiroshima

AJM300/CT3 trial site 74, Hiroshima

AJM300/CT3 trial site 62, Kyoto

AJM300/CT3 trial site 7, Kyoto

AJM300/CT3 trial site 48, Nagasaki

AJM300/CT3 trial site 65, Okayama

AJM300/CT3 trial site 1, Osaka

AJM300/CT3 trial site 37, Ōita

AJM300/CT3 trial site 20, Saga

AJM300/CT3 trial site 25, Saga

AJM300/CT3 trial site 27, Toyama

Sponsors
All Listed Sponsors
collaborator

Kissei Pharmaceutical Co., Ltd.

INDUSTRY

lead

EA Pharma Co., Ltd.

INDUSTRY